KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Other financing activities (2016 - 2025)

LifeMD's Other financing activities history spans 10 years, with the latest figure at -$8.6 million for Q4 2025.

  • For Q4 2025, Other financing activities fell 377.45% year-over-year to -$8.6 million; the TTM value through Dec 2025 reached -$773658.0, down 106.32%, while the annual FY2025 figure was -$773658.0, 106.32% down from the prior year.
  • Other financing activities reached -$8.6 million in Q4 2025 per LFMD's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.5 million in Q1 2022 to a low of -$8.6 million in Q4 2025.
  • Average Other financing activities over 5 years is $2.4 million, with a median of $2.9 million recorded in 2023.
  • Peak YoY movement for Other financing activities: soared 2325.21% in 2021, then tumbled 377.45% in 2025.
  • A 5-year view of Other financing activities shows it stood at $3.1 million in 2021, then plummeted by 39.42% to $1.9 million in 2022, then skyrocketed by 93.44% to $3.6 million in 2023, then dropped by 14.83% to $3.1 million in 2024, then crashed by 377.45% to -$8.6 million in 2025.
  • Per Business Quant, the three most recent readings for LFMD's Other financing activities are -$8.6 million (Q4 2025), $3.2 million (Q3 2025), and $2.1 million (Q2 2025).